A Covid-19 vaccine could be broadly rolled out in the United States by the middle of 2021 or a little later, the head of the federal government’s disease control agency said.
Eli Lilly announced interim proof-of-concept data from the company’s BLAZE-1 Phase II clinical trial of LY-COV555, a neutralizing antibody therapy for Covid-19.
U.S-based cancer testing startup Grail Inc., a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) with the U.S. Securities and Exchange Commission.
Qiagen readies launch of rapid COVID-19 antigen test (Reuters) – German diagnostic test maker Qiagen on Tuesday said it planned to launch a COVID-19 antigen test that can provide results […]
The U.S. Food and Drug Administration approved Switzerland-based pharmaceutical company Roche’s HIV-1/HIV-2 qualitative test for use on the fully automated Cobas 6800/8800 Systems.
Antibody levels against the novel coronavirus rose and then held steady for up to four months in more than 90% of recovered Covid-19 patients in Iceland, according to a published study.
The U.S. government will send an “overwhelming majority” of the rapid Covid-19 tests purchased from Abbott Laboratories to governors of states and territories to support school reopenings and other critical tasks, an administration official said at a press briefing.
The Trump administration will purchase 150 million rapid coronavirus tests from Abbott Laboratories for about $750 million, a White House spokeswoman said.
The U.S. Food and Drug Administration issued Emergency Use Authorization (EUA) for Abbott’s BinaxNOW COVID-19 Ag Card rapid test for detection of Covid-19 infection.
More U.S. colleges were grappling with high numbers of students testing positive for the coronavirus just days into the start of the fall semester after some universities rolled back their campus reopening plans in recent weeks.
